ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

ZINBRYTA
Multiple sclerosis
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

ZINBRYTA Rx

Generic Name and Formulations:
Daclizumab 150mg/mL; soln for SC inj.

Company:
AbbVie and Biogen

Therapeutic Use:

Indications for ZINBRYTA:

Treatment of relapsing forms of multiple sclerosis.

Adult:

Give as SC inj into the thigh, abdomen, or back of upper arm. 150mg once monthly. If AST/ALT >5×ULN or total bilirubin >2×ULN or ALT/AST ≥3–<5×ULN and total bilirubin >1.5–<2×ULN, interrupt or discontinue dose as appropriate (see full labeling).

Children:

<17yrs: not recommended.

Contraindications:

Pre-existing hepatic disease or hepatic impairment, including ALT or AST ≥2×ULN. History of autoimmune hepatitis or other autoimmune condition involving the liver.

Warnings/Precautions:

Risk of serious hepatic injury, including autoimmune hepatitis (discontinue if suspected) and other immune-mediated disorders (eg, skin reactions, lymphadenopathy, non-infectious colitis); may require systemic corticosteroids or immunosuppressants; ­consider discontinuing if serious immune-mediated disorders develop. History of skin conditions (eg, eczema, psoriasis). Evaluate and treat (if positive) for tuberculosis (esp. in high-risk patients) prior to initiation. Screen for hepatitis B/C prior to initiation. Tuberculosis or other severe active infection: avoid starting treatment until controlled. If serious infection develops, consider withholding until resolved. Obtain serum ALT/AST and total bilirubin prior to initiation, monthly, and before the next dose; follow LFTs monthly for 6 months after last dose. Depressive disorders. Monitor for new or worsening symptoms of depression and/or suicidal ideation; consider discontinuing if severe. Discontinue if anaphylaxis or other allergic reactions occur; do not restart. Pregnancy. Nursing mothers.

Interactions:

Avoid live virus vaccines during and up to 4 months after discontinuation. Caution with concomitant hepatotoxic drugs, including non-prescription products (eg, herbals, dietary supplements).

Pharmacological Class:

Interleukin-2 (IL-2) receptor blocking antibody.

Adverse Reactions:

Nasopharyngitis, upper respiratory tract infection, rash, influenza, dermatitis, oropharyngeal pain, bronchitis, eczema, lymphadenopathy, depression, increased ALT; hepatic injury, immune-mediated disorders, acute hypersensitivity.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringe—1

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs